Taken together, these findings suggest that methylation classes are superior to WHO grade for predicting clinical behavior, especially in the case of WHO grade 2 tumors, and that although NF2 mutational status may not be an entirely specific predictor for clinical behavior, non-NF2 driver mutations may be useful in identifying meningiomas with a more benign clinical course. This evidence concerns the gene NF2 and meningioma.